Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ibrahim Almasry

Internal Medicine East Setauket, NY Medical Doctor

NPI 1518953462 CMS profile 159977

26 Research Way, East Setauket, NY 11733

Open in the dashboard

General payments

$118,744

342 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ibrahim Almasry of East Setauket, NY is reported in the CMS Open Payments database as having received $118,744 across 342 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,388 64
2024 General $9,934 36
2023 General $21,301 54
2022 General $25,487 39
2021 General $16,518 31
2020 General $11,732 23
2019 General $30,382 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ibrahim Almasry
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ibrahim Almasry were reported at $3,388. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ibrahim Almasry Internal Medicine median Middle half National median
2019 $30,382 $159 $48–$570 $163
2020 $11,732 $119 $33–$402 $114
2021 $16,518 $135 $37–$521 $132
2022 $25,487 $141 $42–$496 $149
2023 $21,301 $149 $45–$519 $160
2024 $9,934 $154 $47–$537 $164
2025 $3,388 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $108,864 170 payments
  2. Medtronic, Inc. $5,977 102 payments
  3. Abbott Laboratories $2,504 22 payments
  4. Biotronik Inc. $703 9 payments
  5. Medtronic Vascular, Inc. $237 19 payments
  6. Atricure, Inc. $96 3 payments
  7. Pfizer Inc. $89 4 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $41 2 payments
  9. Kestra Medical Technology Services, Inc. $41 1 payment
  10. Philips Electronics North America Corporation $36 1 payment
  11. Other $156 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $90,100 71 payments
  2. Travel and Lodging $20,458 74 payments
  3. Food and Beverage $8,050 195 payments
  4. Education $75 1 payment
  5. Consulting Fee $61 1 payment
Products named General payments · program years 2019–2025
  1. EMBLEM MRI S-ICD $25,431 24 payments
  2. S-ICD System Magnet $21,740 18 payments
  3. EMBLEM $9,790 22 payments
  4. EMBLEM S ICD ELECTRODE DELIVERY SYSTEM Pain Management $8,115 5 payments
  5. EMBLEM S-ICD ELECTRODE DELIVERY SYSTEM $7,800 2 payments
  6. EMBLEM S ICD ELECTRODE DELIVERY SYSTEM Tachy $6,750 8 payments
  7. GENERAL THERAPIES General Therapies $5,662 21 payments
  8. GENERAL THERAPIES Pain Management $5,000 2 payments
  9. General Therapies Therapies $5,000 2 payments
  10. General - Vascular Access $2,500 8 payments
  11. Other $18,755 220 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

74

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$50,900

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

62.2%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 31 $49,847
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 15 $521
Amiodarone Hcl Generic 16 $278
Metoprolol Succinate Generic 12 $252

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$482,197

Medicare's payments for the services billed

Medicare patients

904

Average age 78

Services billed

4,693

404 women, 500 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 73%
Ischemic heart disease 65%
Heart failure 54%
Arthritis 52%
Diabetes 43%
Chronic kidney disease 40%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Scientific Affairs, LLC $29
$29 — —
CLEVIPREX
  • CHIESI USA, INC. $9
$9 — —
KENGREAL
  • CHIESI USA, INC. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

342 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record